The Short Report – November 22, 2022: Feds order Chinese divestment in critical minerals; new cybersecurity task force; Canada in top 15 “talent competitive” countries, open science awards, and more
Organization: Roche
UBC and partners sign major licensing deal with Roche
The Univ of British Columbia has completed its largest licensing agreement to date for a promising treatment for advanced prostate cancer. The agreement with Roche, a Basel, Switzerland-based multinational, was signed by UBC and the Vancouver Coastal Health Research Institute which co-host the Vancouver Prostate Centre where the new drug technology was developed and is…
GSK forges novel R&D partnerships with CDRD
GlaxoSmithKline (GSK) has entered into a two-part R&D collaboration with the Centre for Drug Research and Development (CDRD) and its commercial arm CDRD Ventures Inc (CVI). The novel agreement will see GSK support early-stage projects through CDRD via the GSK-CDRD Innovation Fund. These projects will engage academic investigators at CDRD’s affiliated institutions or hospital-based research…
Isotechnika receives $21.9M milestone from Roche
Isotechnika Inc, Edmonton, has received $21.9 million from Roche following the completion of its Phase II clinical trial of a new psoriasis drug. The $8.355 million in cash and $13.545 million in equity represents one of the largest milestone payments for a Canadian biotech company. The payment was triggered following positive results from Isotechnika’s trial…